comparemela.com
Home
Live Updates
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S : comparemela.com
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the...
Related Keywords
United States
,
Washington
,
American
,
Kevin Moran
,
Mihaelh Polymeropoulos
,
Exchange Commission
,
Twitter
,
Drug Administration
,
Vanda Pharmaceuticals Inc
,
Vanda Pharmaceuticals
,
Investigational New Drug
,
Charcot Marie Tooth
,
Future Medicine
,
Note Regarding Forward Looking
,
Financial Condition
,
Annual Report
,
Quarterly Reports
,
Current Reports
,
Vice President
,
Chief Financial Officer
,
comparemela.com © 2020. All Rights Reserved.